XM does not provide services to residents of the United States of America.
T
T

Teva

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug

US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug Lower court found Norwich generic infringes Salix patents Alvogen has Xifaxan generic deals with Teva, Sun, Sandoz By Blake Brittain WASHINGTON, Nov 18 (Reuters) - The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's BHC.TO blockbuster diarrhea drug Xifaxan.
T

Teva Pharm CEO says will work productively with Trump administration

Teva Pharm CEO says will work productively with Trump administration JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday. "Our job, as always, is to work productively with any administration, and we've shown we can do that, and we will absolutely do that," Francis told Reuters after the Israeli drugmaker issued strong third-quarter results.
T

Teva Pharma's listed shares up after lifting 2024 forecast, upbeat Q3 results

BUZZ-Teva Pharma's US-listed shares up after lifting 2024 forecast, upbeat Q3 results ** U.S.-listed shares TEVA.N of Israel-based Teva Pharmaceutical rise 2.1% to $19.16 premarket ** Co raises its 2024 rev. and earnings forecast after beating Q3 profit forecasts, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease ** Raises 2024 rev.
T

Teva Pharmaceutical raises 2024 outlook as Q3 profit beats estimates

UPDATE 2-Teva Pharmaceutical sees more growth in 2025 after strong Q3 Adds CEO comments, financial details, company background, paragraphs 2-3, 7-9 and 14 Teva raises 2024 revenue and earnings guidance after strong Q3 results CEO Richard Francis expects continued growth in 2025, including biosimilar business Teva fined over $500 million by European Commission, plans to appeal By Steven Scheer JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA raised its 2024 revenue and earnings
T

Teva Pharmaceutical third-quarter profit, revenue top estimates

Teva Pharmaceutical third-quarter profit, revenue top estimates JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries TEVA.TA reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease. The world's largest generic drugmaker said on Wednesday it earned 69 cents per diluted share excluding one-time items in the July-September quarter, up from 60 cents per share a year earlier.
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.